Radiation Oncology
RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.
19 Sep, 2022 | 12:31h | UTCIntensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
My first Tweetorial 🧵 2 year toxicity results of PACE B published here. Big thanks to the 🇬🇧🇨🇦 and🇮🇪collaborators and the 874 men with prostate cancer who made this trial possible https://t.co/mERz2ox8TM
— Alison Tree 💙🇺🇦 (@alison_tree) September 14, 2022
RCT | Busulfan plus Cyclophosphamide is noninferior to total body irradiation plus Cyclophosphamide for adults Acute B Lymphoblastic Leukemia.
11 Sep, 2022 | 22:24h | UTC
Guideline | Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer.
1 Sep, 2022 | 11:53h | UTC
Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.
31 Aug, 2022 | 11:45h | UTCDe-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV
— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022
Systematic Review | Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
26 Aug, 2022 | 13:11h | UTC
RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.
25 Aug, 2022 | 12:13h | UTCEffect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)
Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA
The contemporary management of cancers of the sinonasal tract in adults.
16 Aug, 2022 | 13:39h | UTC
RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.
9 Aug, 2022 | 12:46h | UTCRadiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
RCT | Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus.
9 Aug, 2022 | 12:24h | UTCCommentary: Esophagus-Sparing Radiation Fails QOL Test in Lung Cancer— Esophageal-specific quality of life no better, but treatment reduced symptomatic esophagitis – MedPage Today (free registration required)
Commentary on Twitter
PROACTIVE was a phase 3 RCT of 90 pts with incurable lung cancer treated with esophageal sparing IMRT vs. standard palliative RT. ES-IMRT did not improve FACT-E ECS quality of life scores at 2wks but reduced grade≥2 esophagitis (24% vs. 2%). https://t.co/ExIp22WBPe #RadOnc #LCSM pic.twitter.com/lX8lD4Duja
— JAMA Oncology (@JAMAOnc) February 24, 2022
RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.
8 Aug, 2022 | 11:36h | UTCPartial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
ASTRO Guideline | Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma.
29 Jul, 2022 | 12:33h | UTC
Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.
29 Jul, 2022 | 12:23h | UTC
Commentary on Twitter
In this cohort study of patients with localized prostate cancer, radiotherapy was associated with a small increase in the risk of developing a second primary cancer. https://t.co/YsrNo3FKwM
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.
19 Jul, 2022 | 12:58h | UTCDeintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentaries:
Commentary on Twitter
Less is more? 🤔 2-cycle cisplatin concurrent chemoradiotherapy is not inferior to 3-cycles based on 3-yr PFS in treating locoregionally advanced nasopharyngeal ca w/preRX EBV DNA levels < 4000.QOL & toxicity improved w/ less chemo https://t.co/XovHi2P06W pic.twitter.com/JJqiC8wnWW
— Journal of Clinical Oncology (@JCO_ASCO) January 25, 2022
Phase 2 RCT | Efficacy of preoperative mFOLFIRINOX vs. mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas.
15 Jul, 2022 | 12:29h | UTCEfficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer – JAMA (free for a limited period)
Commentary on Twitter
Ph 2 trial of 126 pts w/borderline resectable pancreatic ductal adenoCa shows 18 mo OS after neoadjuvant mFOLFIRINOX of 66.7%, favorable vs. historical data; 18m OS if mFOLFORINOX then hypofract RT is 47.3%, if chemo then pancreatectomy is 87.5%. https://t.co/wOMNrTOAzm
— JAMA Oncology (@JAMAOnc) July 14, 2022
Female erectile tissues and sexual dysfunction after pelvic radiotherapy: a scoping review.
13 Jul, 2022 | 11:23h | UTC
Phase II RCT | Proton craniospinal irradiation vs. photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.
13 Jul, 2022 | 11:09h | UTCRandomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis – Journal of Clinical Oncology (link to abstract – $ for full-text)
Network M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
Long-term results of RCT: Radiotherapy to the prostate for men with metastatic prostate cancer.
10 Jun, 2022 | 11:10h | UTC
ESTRO-ACROP guideline on surface guided radiation therapy.
7 Jun, 2022 | 10:53h | UTCESTRO-ACROP guideline on surface guided radiation therapy – Radiotherapy & Oncology
Commentary on Twitter
Now available! First European guideline on Surface Guided Radiation Therapy (SGRT): ESTRO-ACROP guideline on surface guided radiation therapy👉https://t.co/YC8Vk8g4h1 @OncologyAdvance @RadiotherapyOn1 #Radonc #Radiotherapy #Oncology
— ESTRO (@ESTRO_RT) June 2, 2022
ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.
7 Jun, 2022 | 10:52h | UTC
M-A: Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer.
3 Jun, 2022 | 10:46h | UTC
Phase 2 RCT: Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy.
2 Jun, 2022 | 10:34h | UTCEfficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Visual Abstract: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy
M-A: Stereotactic radiosurgery vs. whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer.
30 May, 2022 | 10:41h | UTCStereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)
RCT: Effect of supine vs. prone breast radiotherapy on acute toxic effects of the skin among women with large breast size.
27 May, 2022 | 11:51h | UTCEffect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (free for a limited period)
Commentary on Twitter
Adjuvant breast radiotherapy in the prone position decreases acute skin toxicity in women with large breast size, as demonstrated by this multicenter randomized clinical trial. https://t.co/6Emr2Hy5KH #BCSM #RadOnc
— JAMA Oncology (@JAMAOnc) May 26, 2022
AUA/ASTRO Guideline: Clinically localized prostate cancer.
13 May, 2022 | 11:10h | UTCHomepage: Clinically Localized Prostate Cancer: AUA/ASTRO Guideline – American Urological Association
Part I: Introduction, Risk Assessment, Staging and Risk-Based Management
Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up
Part III: Principles of Radiation and Future Directions
Related:
Therapies for Clinically Localized Prostate Cancer – Agency for Healthcare Research and Quality
Radical prostatectomy versus deferred treatment for localised prostate cancer – Cochrane Library